SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David Culver who wrote (1212)3/29/1999 9:48:00 PM
From: Chuca Marsh  Read Replies (1) of 1501
 
Maybe it was ARIS ...not ARIAD...the one that was sponsored by Cowens...it was in that 1996 Biotech Book. They sponsered that IPO I was referring.
LOOK: Maybe this is why ARAID stuck in my mind:
Pangea Systems Tools Used to Design DNA
Expression Chips for Hoechst Marion
Roussel

Business Wire - February 02, 1999 08:21

OAKLAND, Calif.--(BW HealthWire)--Feb. 2, 1999--Pangea Systems,
Inc. announced today that its computational tools are being used by Hoechst
Marion Roussel and the Hoechst-ARIAD Genomics Center (a joint venture
of Hoechst Marion Roussel and ARIAD Pharmaceuticals) to efficiently and
accurately design custom gene expression chips from full length gene
sequences and clustered gene fragments, called expressed sequence tags
(ESTs), identified by Hoechst Marion Roussel.

The new chips will enable Hoechst Marion Roussel to study gene families of
potential therapeutic interest and validate their usefulness as drug targets.

"Pangea's software is particularly valuable because it allows us to
automatically integrate information from our compiled internal databases into
designs for the manufacture of gene expression chips," said Rich Hamer,
Ph.D., head of Hoechst Marion Roussel's Global Bioinformatics Group.
"With the help of Pangea's tools, we were able to significantly accelerate our
internal chip design process."

"This relationship between Pangea and Hoechst Marion Roussel further
validates our chip design software, and illustrates how Pangea is closing the
gap between genome sequencing efforts and drug target validation," said John
Couch, chief executive officer of Pangea Systems, Inc. He noted that the
Hoechst-ARIAD Genomics Center had previously licensed Pangea's EST
Clustering and Alignment tools for use in the company's bioinformatics
programs.

Pangea's chip design tools uniquely automate the identification and selection
of gene sequences for incorporation in custom DNA expression chips, rapidly
producing error-free sequence sets in the appropriate format for chip
manufacture. As a result, sequence selection and chip design efforts that
previously required weeks to months of hand labor can be accomplished
automatically in hours with greatly improved accuracy.

"Pangea's chip design software amplifies the gains that EST Clustering and
Alignment tools provide," added Couch. "One component of the Pangea chip
design tools automatically segregates and classifies gene isoforms and
polymorphisms that may be linked to disease. The Pangea tools automatically
identify optimal regions for chip design, and output the results into the input
format developed by the leading chip manufacturer, Affymetrix."

Hoechst Marion Roussel is the pharmaceutical company of Hoechst AG. The
Hoechst-ARIAD Genomics Center, a joint venture of Hoechst Marion
Roussel and ARIAD Pharmaceuticals (Nasdaq:ARIA), utilizes functional
genomics technologies to identify novel therapeutic targets and therapeutic
proteins.

Pangea Systems, Inc. is a leading provider of software for advanced
bioinformatics -- the application of information technology to life science
research and development.

The company's mission is to provide pharmaceutical and biotechnology
companies with operationally proven software applications, unique scientific
(computational) tools, an open computing environment, and value-added
professional services that integrate the collection, organization and analysis of
biological and biochemical information. In doing so, Pangea's bioinformatics
software simplifies and accelerates the drug discovery process in ways never
before achieved.

Incorporated in 1993, Pangea Systems, Inc. is a privately held, Oakland,
Calif.-based company. For more information, contact Pangea Systems, Inc.
at 510/628-0100, or e-mail us at info-pr@pangeasystems.com or visit
pangeasystems.com.

Note to Editors: Pangea Systems is a registered trademarks of Pangea
Systems, Inc. The Pangea Systems logo, is a trademarks of Pangea Systems.
Inc. All other trademarks, brands and names are property of their respective
owners.

CONTACT: Pangea Systems, Inc.
Marie Martin, 510/628-0100
mariem@pangeasystems.com
or
J. Kureczka Associates
Joan Kureczka, 415/821-2413
jkureczka@aol.com
Chuca
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext